checkAd

     158  0 Kommentare MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) - Seite 3


    CONTACT:
      Sasha Damouni Ellis
    Vice President, Investor Relations & Corporate Communications
    Marinus Pharmaceuticals, Inc.
    484-253-6792
    sdamouni@marinuspharma.com

    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) - Seite 3 RADNOR, Pa., March 23, 2020 (GLOBE NEWSWIRE) - Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company”, “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today …